Adaptive Biotechnologies Corporation - Common Stock (ADPT)
9.0300
-0.2400 (-2.59%)
NASDAQ · Last Trade: May 11th, 12:10 PM EDT
Detailed Quote
Previous Close
9.270
Open
9.400
Bid
9.000
Ask
9.760
Day's Range
9.025 - 9.503
52 Week Range
2.990 - 10.28
Volume
1,151,980
Market Cap
1.30B
PE Ratio (TTM)
-9.505
EPS (TTM)
-1.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,963,872
Chart
About Adaptive Biotechnologies Corporation - Common Stock (ADPT)
Adaptive Biotechnologies is a biotechnology company that focuses on harnessing the power of the immune system for disease detection and treatment. The company specializes in developing advanced diagnostic tests that analyze the DNA and RNA of immune cells to identify specific immune responses related to various diseases, including cancer and autoimmune disorders. By leveraging large-scale sequencing technology and sophisticated bioinformatics, Adaptive aims to provide physicians with critical insights that can help guide personalized treatment options and improve patient outcomes. Through its innovative platform, the company seeks to transform how diseases are diagnosed and treated, making significant contributions to the field of precision medicine. Read More
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025.
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024.
SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 11, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuum
